NCT01970787已完成不适用
A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Clearance of Anal HSIL (High Grade Squamous Intraepithelial Lesion (HSIL)
研究概览
简要总结
This is a Single-center prospective pilot trial involving up to 22 subjects. This study will assess the feasibility, safety, and efficacy of radiofrequency ablation (RFA) to the anal canal using the FDA cleared HALO Ablation System to eradicate anal HSIL lesions in HIV-negative subjects with intra-anal intraepithelial neoplasia (AIN). The study intervention will demonstrate that a reasonable proportion of subjects will be histologically cleared of their anal HSIL within the ETZ in a tolerable and relatively safe manner
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-75 years
- •HRA 2 to 12 weeks prior to the 0 month RFA visit yielding one or more flat, non-condylomatous biopsy-proven HSILs that are
- •Located entirely within in the eligible treatment zone
- •Contiguous with the squamocolumnar junction Eligible treatment zone (ETZ) is defined as
- •3 cm above the dentate line to the anocutaneous line
- •Half of the anorectal circumference (meaning no more than two contiguous quadrants)
- •If female of child-bearing age, negative pregnancy test within 8 weeks of the 0 month RFA visit and declared intent to remain on birth control throughout the trial, or, declaration of infertility defined as subject report of status as post-menopausal or surgically sterile (status post hysterectomy or tubal ligation).
- •HIV negative, ELISA/Western blot test obtained within 12 weeks of the 0 month RFA visit
排除标准
- •Any biopsy-proven HSIL entirely outside of the ETZ
- •Any biopsy-proven HSIL partially within the ETZ (for example, an HSIL lesion with extension to the perianal skin)
- •Any condylomas in the eligible treatment zone > 1/2 cm diameter
- •Note: Condylomas in the eligible treatment zone < 1/2 cm in diameter must be excised or cauterized (not treated topically or with IRC) before or during Visit 1 (0 month RFA visit)
- •Any anal or rectal pathology requiring treatment including ulcer, fistula, fissure, stenosis or proctitis
- •History of or present anal or rectal cancer
- •History of pelvic radiation therapy
- •History of HPV vaccination or plans to initiate HPV vaccination during the trial
- •History of ablation or resection therapy within the ETZ other than cauterization or excision of condyloma(s)
- •History of topical therapy (Imiquimod, 5-FU) within 6 months prior to the 0 month RFA visit within the ETZ
- •Hemorrhoids > grade II
- •Fecal incontinence (that the investigator feels may impair healing)
- •Concurrent disease requiring systemic immunosuppression therapy
- •Concurrent malignancy requiring systemic therapy
- •Life expectancy < 2 years
结局指标
主要结局
Clearance of Anal HSIL (High Grade Squamous Intraepithelial Lesion (HSIL)
时间窗: 12 months
Participants with histologic clearance of anal HSIL within the ETZ (eligible treatment zone) at 12 months from first RFA treatment
次要结局
- Feasibility and Ease of Technique(12 months)
- Progression of HSIL to Cancer(12 months)
- Adverse Events(12 months)
- Tolerability(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Radiofrequency Ablation of Low Risk Papillary Thyroid MicrocarcinomaPapillary Thyroid MicrocarcinomaThyroid CancerNCT03432299Seoul National University Hospital100
已完成
1 期
RF Ablation of Atrial FibrillationAtrial FibrillationNCT00265629C. R. Bard20
已完成
不适用
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung CancerLung CancerNCT00109876Alliance for Clinical Trials in Oncology54
招募中
不适用
An Exploratory Study of Focal Pulse Ablation System in the Treatment of Atrial ArrhythmiaNCT06157437Hangzhou Dinova EP Technology Co., Ltd10
已完成
不适用
Evaluation of the Safety and Efficacy of the CardioPulseTM PuLsed fiEld Ablation SystEm in Patients With Paroxysmal Atrial Fibrillation (PLEASE-AF Study)Paroxysmal Atrial FibrillationNCT05114954Hangzhou Dinova EP Technology Co., Ltd158